1. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
- Author
-
Ahmet Emre Eskazan, Sevil Sadri, and Dilek Keskin
- Subjects
Oncology ,medicine.medical_specialty ,Myeloid ,medicine.drug_class ,Dasatinib ,Fusion Proteins, bcr-abl ,Pharmaceutical Science ,Antineoplastic Agents ,Comorbidity ,Review ,Tyrosine-kinase inhibitor ,03 medical and health sciences ,0302 clinical medicine ,tyrosine kinase inhibitor ,chronic myeloid leukemia ,Internal medicine ,Acute lymphocytic leukemia ,hemic and lymphatic diseases ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Drug Discovery ,medicine ,Advanced disease ,Humans ,Pharmacology ,business.industry ,Patient Selection ,Myeloid leukemia ,Protein-Tyrosine Kinases ,medicine.disease ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Immunology ,Mutation ,business ,Tyrosine kinase ,030215 immunology ,medicine.drug - Abstract
Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intolerance, as well as in the frontline setting in patients with chronic myeloid leukemia-chronic phase, and also in patients with advanced disease. It is also utilized in Philadelphia chromosome-positive acute lymphocytic leukemia. While choosing the appropriate tyrosine kinase inhibitor (ie, dasatinib) for each individual patient, comorbidities and BCR-ABL1 kinase domain mutations should always be taken into consideration, among other things. This review mainly focuses on patient selection prior to dasatinib administration in the treatment of chronic myeloid leukemia.
- Published
- 2016